EUVIMEDOdkrijte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review

Candice L Garwood iD, Katherine P Cabral iD, Roy Brown iD, Dave L Dixon iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-01 · 45 (1) · 54-65

DOI: 10.1002/phar.4635 ↗

At a glance

Übersichtsarbeit in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2024-12-16. Written by Candice L Garwood and 3 co-authors. Institution: Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA. Major MEDLINE topics: Cholesterol, LDL, Atherosclerosis, PCSK9 Inhibitors, Anticholesteremic Agents. Cited 37 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Lowering low‐density lipoprotein cholesterol (LDL‐C) levels is a primary strategy to reduce ASCVD risk. Although statin therapy remains the initial therapy of choice to reduce LDL‐C and ASCVD risk, statin intolerance and suboptimal LDL‐C lowering response prompts the need for additional non‐statin therapies. Ezetimibe and bempedoic acid are reasonable options but they modestly reduce LDL‐C levels (15% to 25%). Therapies directed at the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, however, reduce LDL‐C levels by 50%–60% when added to background statin therapy. PCSK9 is an enzyme synthesized by the liver that facilitates the degradation of LDL receptors and prevents their recycling to the hepatocyte surface to remove LDL‐C from circulation. Approaches to inhibit this effect have centered on monoclonal antibodies (mAbs) (alirocumab, evolocumab) targeting PCSK9 functionality and small interfering RNA (siRNA) therapies (inclisiran) targeting the hepatic synthesis of PCSK9. Randomized controlled trials have demonstrated beneficial cardiovascular outcomes of PCSK9 mAbs, but such evidence is not yet available for inclisiran. Current clinical practice guidelines generally recommend PCSK9‐directed therapies for higher‐risk patients with established ASCVD and those with familial hypercholesterolemia. This approach is, in part, due to their cost and uncertain economic value, but also because these therapies require subcutaneous administration, which is not preferred by some patients. Oral therapies targeting PCSK9 are, however, in development. This scoping review covers the development of current and emerging PCSK9‐directed therapies, their efficacy, safety, and role in clinical practice.

Subjects

MeSH terms (MEDLINE)

Cholesterol, LDLAtherosclerosisPCSK9 InhibitorsAnticholesteremic AgentsHumansProprotein Convertase 9Antibodies, MonoclonalAnimalsAntibodies, Monoclonal, Humanized

Author keywords

PCSK9alirocumabatherosclerotic cardiovascular diseaseevolocumabinclisiran

Substances

Proprotein Convertase 9PCSK9 protein, humanCholesterol, LDLPCSK9 InhibitorsAnticholesteremic AgentsAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
  • Department of Pharmacy, Harper University Hospital, Detroit Medical Center, Detroit, Michigan, USA.
  • Department of Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, New York, USA.
  • Capital Cardiology Associates, Albany, New York, USA.
  • Health Sciences Library, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.

ORCID profiles: Candice L Garwood, Katherine P Cabral, Roy Brown, Dave L Dixon

Cite

APA

Garwood, C. L., Cabral, K. P., Brown, R., & Dixon, D. L. (2025). Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(1), 54-65. https://doi.org/10.1002/phar.4635

Vancouver

Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(1):54-65. doi:10.1002/phar.4635

BibTeX
@article{Garwood2025,
  author = {Garwood, Candice L and Cabral, Katherine P and Brown, Roy and Dixon, Dave L},
  title = {Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  volume = {45},
  number = {1},
  pages = {54--65},
  doi = {10.1002/phar.4635}
}
Start for free →